Literature DB >> 7593612

Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.

M W Chang1, E Barr, M M Lu, K Barton, J M Leiden.   

Abstract

Vascular smooth muscle cell (VSMC) proliferation after arterial injury is important in the pathogenesis of a number of vascular proliferative disorders, including atherosclerosis and restenosis after balloon angioplasty. Thus, a better understanding of the molecular mechanisms underlying VSMC proliferation in response to arterial injury would have important therapeutic implications for patients with atherosclerotic vascular disease. The p21 protein is a negative regulator of mammalian cell cycle progression that functions both by inhibiting cyclin dependent kinases (CDKs) required for the initiation of S phase, and by binding to and inhibiting the DNA polymerase delta co-factor, proliferating cell nuclear antigen (PCNA). In this report, we show that adenovirus-mediated over-expression of human p21 inhibits growth factor-stimulated VSMC proliferation in vitro by efficiently arresting VSMCs in the G1 phase of the cell cycle. This p21-associated cell cycle arrest is associated both with significant inhibition of the phosphorylation of the retinoblastoma gene product (Rb) and with the formation of complexes between p21 and PCNA in VSMCs. In addition, we demonstrate that localized arterial infection with a p21-encoding adenovirus at the time of balloon angioplasty significantly reduced neointimal hyperplasia in the rat carotid artery model of restenosis. Taken together, these studies demonstrate the important role of p21 in regulating Rb phosphorylation and cell cycle progression in VSMC, and suggest a novel cytostatic gene therapy approach for restenosis and related vascular proliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593612      PMCID: PMC185876          DOI: 10.1172/JCI118281

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

Review 1.  Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions.

Authors:  D W Muller; S G Ellis; E J Topol
Journal:  J Am Coll Cardiol       Date:  1991-05       Impact factor: 24.094

2.  Physical interaction of the retinoblastoma protein with human D cyclins.

Authors:  S F Dowdy; P W Hinds; K Louie; S I Reed; A Arnold; R A Weinberg
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

3.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

4.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.

Authors:  J Kato; H Matsushime; S W Hiebert; M E Ewen; C J Sherr
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

Review 5.  The restenosis paradigm revisited: an alternative proposal for cellular mechanisms.

Authors:  R S Schwartz; D R Holmes; E J Topol
Journal:  J Am Coll Cardiol       Date:  1992-11-01       Impact factor: 24.094

6.  Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery.

Authors:  M W Chang; T Ohno; D Gordon; M M Lu; G J Nabel; E G Nabel; J M Leiden
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

Review 7.  The pathogenesis of atherosclerosis: a perspective for the 1990s.

Authors:  R Ross
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

8.  Functional interactions of the retinoblastoma protein with mammalian D-type cyclins.

Authors:  M E Ewen; H K Sluss; C J Sherr; H Matsushime; J Kato; D M Livingston
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins.

Authors:  H Matsushime; M E Ewen; D K Strom; J Y Kato; S K Hanks; M F Roussel; C J Sherr
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

10.  Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor.

Authors:  V Lindner; N E Olson; A W Clowes; M A Reidy
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

View more
  43 in total

1.  Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo.

Authors:  D G Macejak; H Lin; S Webb; J Chase; K Jensen; T C Jarvis; J M Leiden; L Couture
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 2.  Gene therapy for restenosis.

Authors:  R C Smith; K Walsh
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

3.  Novel methods for adenovirus-mediated gene transfer to blood vessels in vivo.

Authors:  H Ooboshi; C D Ríos; D D Heistad
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

4.  Identification of cyclin D3 as a direct target of E2A using DamID.

Authors:  Siyuan Song; Jonathan Cooperman; Danielle L Letting; Gerd A Blobel; John Kim Choi
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 5.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

6.  MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling.

Authors:  Yasuhiro Nakamura; Saya Suzuki; Takashi Suzuki; Katsuhiko Ono; Ikumi Miura; Fumitoshi Satoh; Takuya Moriya; Haruo Saito; Shogo Yamada; Sadayoshi Ito; Hironobu Sasano
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

7.  Apoptosis, cell proliferation and modulation of cyclin-dependent kinase inhibitor p21(cip1) in vascular remodelling during vein arterialization in the rat.

Authors:  Thaiz Ferraz Borin; Ayumi Aurea Miyakawa; Leandro Cardoso; Luciano de Figueiredo Borges; Giovana Aparecida Gonçalves; Jose Eduardo Krieger
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

Review 8.  Mechanisms and therapeutic potential of microRNAs in hypertension.

Authors:  Lijun Shi; Jingwen Liao; Bailin Liu; Fanxing Zeng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-05-21       Impact factor: 7.851

9.  Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

Authors:  Bumsup Kwon; Pravir Kumar; Han-Kyu Lee; Ling Zeng; Kenneth Walsh; Qinghao Fu; Amey Barakat; Henry W Querfurth
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

10.  NFATc1 targets cyclin A in the regulation of vascular smooth muscle cell multiplication during restenosis.

Authors:  Manjula Karpurapu; Dong Wang; Nikhlesh K Singh; Quanyi Li; Gadiparthi N Rao
Journal:  J Biol Chem       Date:  2008-07-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.